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Abstrad
Oncostatin M (OM) is a cytokine that shares a
strudural and fundional relationship with interleukin
6, leukemia-inhibitory fador, and granuIocyte colony-
stimulating fador. In this report, we tested for
correlations between immediate-early gene expression
and some of the cellular responses elicited by OM. We
determined that OM stimulated a rapid and transient
elevation of EGR-1, c-jun, and c-myc mRNA in human
fibroblasts prior to their proliferation. OM also
stimulated a transient indudion of these genes in Ml
leukemic cells that differentiated into nonreplicating,
macrophage-like cells. The expression of c-myc,
however, decreased significantly as the cells stopped
dividing. Interestingly, OM had no detedable effed on
the expression of EGR-l, c-jun, and c-myc during the
cell cycle arrest of human A375 melanoma cells. Our
results indicate that an early nuclear event associated
with OM adion is the regulation of immediate-early
gene expression. We suggest that the transcription
fadors encoded by the EGR-l, c-jun, and c-myc genes
are utilized in both cell proliferation and
differentiation but are not part of the mechanism by
which OM inhibits A375 cell growth.
Introdudion
OM2 is a 28 kilodalton glycoprotein that was originally
identified by its antitumor cell activity in vitro (1). It has
subsequently been shown to regulate a broad spectrum
of effects in addition to proliferation and has been iden-
tified as a cytokine (2-4). Like many of the factors that
influence inflammatory and immune reactions, OM is
produced by activated monocytes, I-lymphocytes, and
macrophage cells (5, 6). OM acts within a cytokmne net-
work and regulates the production of lL-6 mRNA and
protein in primary endothelial cells (4). OM has been
shown to modulate additional activities such as stimula-
tion of plasmmnogen activator (7) and increasing the level
of LDL receptor on HepG2 cells (8). Examination of the
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primary sequence and gene organization of OM suggests
a structural relationship with other cytokmnes, including
IL-6, LIF, and granulocyte-colony-stimulating factor (9,
10). Combined with a functional relationship to LIF and
IL-6 in stimulating myeloid cell differentiation (9), it has
been suggested that OM is descended, with these other
cytokmnes, from a common ancestral gene (9).
The signal transduction mechanism by which OM me-
diates its activities is presently being investigated. High
affinity receptors with an approximate size of 150 kilo-
daltons have been detected on the surface of a variety
of cell types (ii, 12). Second messenger pathways from
this receptor have been tested in HepC2 cells (8). it was
suggested that the action of OM, which up-regulates LDL
receptor, involves tyrosine kinase phosphorylation, ac-
cumulation of phospholipids, and the stimulation of PKC.
Although the specific signaling pathways activated by
the OM receptor remain unclear, the responses that they
elicit must involve changes in gene transcription. Based
on the actions of many other cytokmnes and peptide
hormones, one of the first sets of genes to be activated
by OM binding to its receptor should be the immediate-
early gene family. These genes, which include EGR-1,
los, myc, and jun, are expressed in the absence of protein
synthesis within minutes of receptor binding (13-15).
Because the immediate-early genes encode regulators of
gene transcription (16-24), their induction by OM would
be important in controlling subsequent gene activity.
Identification of specific members of this family that
respond to OM might provide important clues as to the
molecular actions of this cytokine.
As an initial characterization of the nuclear events
regulated by OM, we have examined the expression of
three immediate-early genes: EGR-1, c-/un, and c-myc.
To determine whether correlations exist between the
regulation of these genes and the biological responses
elicited by OM, we examined three distinct biological
processes regulated by OM: stimulation of human fibro-
blast proliferation, terminal differentiation of murine Ml
ieukemic cells, and the inhibition of human A375 mela-
noma cell proliferation. Our results indicate that EGR-l
and c-jun are rapidly induced by OM in both proliferating
and differentiating cell types, whereas c-myc mRNA is
up-regulated in proliferating cells but down-regulated in
differentiating cells. Interestingly, none of these imme-
diate-early genes was regulated by OM during cell cycle
arrest of A375 cells. Based on the observed regulation of
EGR-1 by TPA in these cells and in an OM-resistant cell
line, we speculate that the inhibition of A375 cell prolif-
eration occurs through a PKC-independent pathway.
Results
Stimulation of Cell Proliferation by OM Is Preceded by
an Indudion of Immediate-Early Gene Expression.
Among the varied responses that OM can elicit in cells
is the enhancement of cell proliferation (1, 12). As shownA
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Fig. 1. OM stimulates prolifer-
ation of human fibroblasts and
immediate-early gene expres-
sion. A, human fibroblasts (2000
cells/well) were incubated for 2
days in DMEM containing 5%
FBS and various amounts of pu-
rified OM. Cells were pulsed
with [‘25ljiododeoxyuridine (0.1
￿Ci/ml) for an additional 5 h. The
amount of radioactivity incorpo-
rated into DNA was determined,
and the data were normalized to
the percentage growth of the
culture relative to cells not
treated with OM. B, in a sepa-
rate experiment, subconfluent
monolayers of human fibroblasts
incubated for 24 h in DMEM
containing 0.5% FBS were ex-
posed to OM (200 pM) for in-
creasing amounts of time. Total
RNA was isolated, and 10 ig/
lane were assayed for EGR-1, c-
jun. c-myc, and -y-actin by North-
em blot analysis. Lane 1, control;
Lanes 2-5, OM treatment for 0.5,
1, 2, and 3 h, respectively. C,
subconfluent monolayers of hu-
man fibroblasts growing in
DMEM containing 5% FBS were
incubated with OM (200 pM) for
1 h. Lane C, control.
in Fig. iA, treatment of human fibroblasts for 2 days with
ng/ml concentrations of OM stimulated a 2.5-fold in-
crease in DNA synthesis relative to control cultures. To
characterize its mitogenic effect, we tested whether OM
could stimulate the transcription of some of the imme-
diate-early genes that have been associated with a pro-
liferation response, such as EGR-l, c-jun, and c-myc (14,
25, 26). Cultures of human fibroblasts, incubated in the
presence of 0.5% FBS for 24 h, were treated with OM
for various intervals. Total cellular RNA was then isolated
and analyzed by Northern analysis. As indicated (Fig. 1B),
EGR-l and c-jun mRNA levels increased within 30 mm
of OM treatment, and by 1 h, the mRNA for these two
genes had risen 20- and 7-fold, respectively. c-myc
mRNA also accumulated significantly (3-fold) during this
interval. Within 2-3 h after OM treatment, the mRNAs
for these three genes returned to pretreatment levels. In
addition to its induction in quiescent cells, EGR-1 mRNA
was markedly increased in exponentially growing human
fibroblasts after 1 h stimulation with OM (Fig. 1C).
OM Stimulates the Differentiation of Mouse Leukemic
Ml Cells and the Down-Regulation of c-myc. Similar to
other cytokines (27-29), OM can stimulate the terminal
differentiation of leukemic Mi cells (9). Associated with
a loss in proliferative capacity, these cells acquire a
macrophage-like phenotype (data not shown). As shown
in Fig. 2A, maximum reduction in [3H}thymidine incor-
poration following a 3-day incubation period was
achieved with as little as 1 ng/ml OM. To investigate
immediate-early gene responses to OM, we analyzed the
RNA isolated from Ml cells treated with OM for different
lengths of time. As shown in Fig. 2B, ECR-1 and c-jun
mRNAs increased 7- and 2.5-fold, respectively, within
the first 3 h. After that, the expression of these genes
returned to basal level. The superinduction of these
genes occurring in the presence of OM and cyclohex-
imide as illustrated in Lane 5 of Fig. 2B is diagnostic of
immediate-early gene expression and indicates that OM
has a direct effect on gene expression that is not de-
pendent on de novo protein synthesis.
It was reported that Ml differentiation, induced by
cytokines such as IL-6 and LIF, is associated with an early
increase in c-myc expression followed by a subsequent
suppression of c-myc (30). The decline in c-myc mRNA
was required for the arrest of Ml cell proliferation (31,
32). One might expect that OM, as a differentiation
inducer of Ml cells, would cause a similar effect. As
shown in Fig. 2C, c-myc mRNA increased during the first
3 h of OM treatment. By 11 h, however, the level of c-
myc mRNA was slightly below the control level, and by
24 h, c-myc mRNA was significantly reduced.
The Inhibition of Human Melanoma Cell Proliferation
by OM Is Not Correlated with a Change in EGR-1, c-jun,
and c-myc mRNA. The effect of OM on A375 cell prolif-
eration was examined by culturing the cells in DMEM
containing 5% FBS with various amounts of OM. After
72 h, DNA synthesis was measured. As demonstrated in
Fig. 3A, the cellular proliferation of human A375 mela-
noma cells was strongly inhibited by OM. The possibility
that immediate-early gene expression in A375 cells
would be altered during this process was examined. A375
cells growing in tissue culture flasks (same cell density as
in Fig. 3A) were treated with OM, and the total cellular
RNA was then isolated and analyzed by Northern analy-
sis. As shown in Fig. 3B, changes in EGR-l, c-myc, and c-
jun mRNA were not detected following exposure to a
very high concentration of OM (20 ng/ml). Because the
mRNAs for these genes are unstable and rapidly de-
graded (33), it seemed possible that any induction of
gene expression caused by OM in A375 cells might be
masked. Therefore, a time course of OM treatment was
repeated with cells incubated in the presence of cyclo-A B ;￿ C
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Fig. 2. Murine Ml cells withdraw from the cell cycle and down-regulate c-myc mRNA in response to OM. A, mouse leukemic Ml cells (10,000 cells/
well), incubated in RPMI 1640 medium containing 5% FBS, were exposed to increasing amounts of purified OM for 72 h, pulsed with 0.1 ￿sCi/well of
[3H]thymidine for an additional 5 h, and then assayed for [3H]thymidine incorporation into DNA. B, in a parallel experiment, Ml cells were incubated
with OM (20 ng/ml) in the presence or absence of cycloheximide (CHX) (10 ￿g/ml). Total RNA was isolated at the indicated times and assayed for
immediate-early gene expression by Northern blot analysis. C, c-myc mRNA levels obtained from Ml cells treated with OM (20 ng/ml) for the indicated
times.
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heximide. As expected, the mRNA levels for these genes
increased following cycloheximide treatment. Significant
differences, however, were not observed between these
cultures and cells treated with cycloheximide and OM.
We conclude that OM does not stimulate the expression
of these genes during its inhibition of A375 cell
replication.
The Inhibition of A375 Cell Proliferation by OM May
Not involve Protein Kinase C. In addition to OM, the
proliferation ofA375 cells is inhibited by TPA and various
cytokines such as IL-6 (Fig. 4A). To determine whether
immediate-early gene expression changes when A375
cells respond to these growth regulators, we examined
EGR-l mRNA levels in cells treated with TPA or IL-6.
Similar to OM, IL-6 failed to induce ECR-1 (Fig. 4B). A
strong induction of this gene did occur, however, follow-
ing treatment with TPA. The observation that TPA in-
duced EGR-l in A375 cells was not unexpected. Protein
kinase C has previously been shown to regulate EGR-1
transcription. However, the fact that the EGR-1 gene is
responsive to TPA in A375 cells, but not OM, may
exclude PKC involvement in OM signal transduction.
A similar conclusion, that PKC does not mediate the
actions of OM in A375 cells, can be drawn from experi-
ments utilizing a variant subclone that is resistant to OM.
Fig. SA demonstrates that in contrast to the parental A375
cells, the 4-1.10” clone (which possesses a similar level
ofthe OM receptor) proliferates normally in the presence
of OM. Sensitivity of these cells to TPA, however, is
retained when one measures inhibition of cell prolifera-
tion (Fig. 58) and ECR-l inducibility (Fig. 5C). Further-
more, the presence of OM in the medium has no effect
on the ECR-l induction by TPA in either cell line. Again,
these results suggest that OM may not utilize PKC in
mediating its effect on A375 cells. Alternatively, growth
inhibition by OM and TPA may be independent of ECR-
1, since inhibition occurs in the absence and presence
of EGR-1 induction.
Discussion
Activation of immediate-early genes is an initial transcrip-
tional event associated with an environmental stimulus
(16-24, 34, 35). The transcription factors encoded by
these genes appear to regulate the phenotypic changes
that occur when cells respond to external signals. In this
study, we have tested whether OM regulates the expres-
sion of EGR-1, c-/un, and c-myc and whether correlations
exist between the expression of these genes and the type
of biological responses elicited by OM.
In mediating a proliferation response in human fibro-
blasts, OM induced immediate-early gene expression.
Within 1 h after OM treatment, the mRNA levels of EGR-
1, c-/un, and c-myc increased 20-, 7-, and 3-fold, respec-
tively. The induction was transient, and within 2-3 h, the
mRNA levels returned to basal level. This expression
profile is similar to the regulation of immediate-early
genes by other growth factors (34), cytokines (33), and
environmental stimuli (35). In general, the rapid accu-
mulation of mRNA results from a direct and transientC
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Fig. 3. The inhibition of A375
cell proliferation by OM does
not involve a change in EGR-i,
c-myc, or c-jun mRNA. A, A375
human melanoma cells were in-
cubated in DMEM containing
5% FBS and various amounts of
pure OM for 72 h. Percentage
growth was calculated as de-
scribed in “Materials and Meth-
ods.” B, subconfluent cultures
were exposed to OM (20 ng/mI),
and total RNA was harvested at
different time points. EGR-1 and
c-myc mRNA levels were meas-
ured by Northern blot analysis
(30 ￿zg/Iane). Lanes 1, 3, and 9,
controls for 0, 1, and 24 h, re-
spectively; Lanes 2 and 4-8, cul-
c - myc #{149}￿#{149} ‘:￿ ￿ W #{149}￿ #{149}, tures treated with OM for 0.5, 1,
2, 4, 8, and 24 h. C, to determine
whether the lack of induction of
18[￿ these genes is due to degrada- 28 ￿ tion of mRNA, cells were treated with OM (20 ng/ml) in the pres- ence and absence of cyclohex- imide (CHX; 10 pg/mI) for the indicated times and then assayed for gene expression.
A
B OM (ng/mi)
123456789
EGR-1 -28S
c-myc ￿
-18 S
activation of transcription. The subsequent drop in
mRNA levels reflects mRNA turnover.
In addition to stimulating fibroblast proliferation, OM
was shown to mediate cell cycle withdrawal and terminal
differentiation of murine Ml cells. Preceding this re-
sponse, and within 3 h of OM addition, the mRNA level
for EGR-1 increased 7-fold and then returned to basal
level. c-jun and c-myc mRNA levels also changed ap-
proximately 3-4-fold during this time interval. The induc-
tion of these genes was less dramatic during Mi cell
differentiation than during fibroblast proliferation. To
help explain this difference, we examined immediate-
early gene induction in Ml cells stimulated to differen-
tiate with lL-6. Similar to OM, lL-6 caused only a modest
increase in ECR-l, c-/un, and c-myc mRNA.3 We suggest
that the extent to which these primary responsive genes
are expressed could be different from one cell type to
another. Other cytokines like granulocyte-macrophage
colony-stimulating factor have also been shown to ele-
vate EGR-l mRNA differentially in cells stimulated to
proliferate and differentiate (33, 36).
One correlation between immediate-early gene
expression and cell behavior that has been observed
repeatedly is the down regulation of c-myc during cell
differentiation (30-32). For Ml cells, this loss of c-myc
mRNA was shown to be required for a complete differ-
entiation response (32). Similar to IL-6 and LIF in evoking
c-myc down-regulation, the majority of c-myc mRNA in
Mi cells was lost after 24 h treatment with OM. This
finding is an additional indication that OM regulates the
differentiation of these cells. Taken together, our data
suggest that OM may play an important role in the growth
and differentiation of hematopoietic cells.
OM has been shown to arrest the proliferation of a
number of human tumor cells in vitro (1, 12). Similar to
IL-i and IL-6 (37, 38), OM has a powerful effect on A375
cells. No change, however, was detected in the mRNA
levels for ECR-1, c-/un, and c-myc following OM treat-
ment. Additional members of the early gene family, in-
cluding c-fos and jun D, were also assayed in these cells,
but changes in their expression were not observed. These
results indicate that the inhibitory action of OM on A375
cells does not involve the regulation of these common
immediate-early genes. This also suggests that the mech-
anism of OM action may be different from that of IL-i
since it was reported that IL-i increased c-jun and c-los
expression during its inhibitory effect on A375 cells (37).
Identification of the target genes specifically regulated
by OM will provide important clues to the mechanism
of inhibition of melanoma cell growth.
The signal transduction mechanism of OM is essen-
tially unknown. Experiments with A375 cells, however,
may provide a clue which eliminates one common sig-
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Fig. 4. Inhibition of A375 cell
proliferation by TPA is preceded
by an induction of EGR-1 mRNA.
A, A375 melanoma cells were
incubated with the indicated
amounts of OM (Onco M), IL-6,
and TPA for 3 days and then
assayed for growth. B, in a par-
allel experiment, cells were in-
cubated with OM (20 ng/ml),
TPA (100 ng/ml), lL-6 (10 ng/mI),
or cycloheximide (10 ￿g/ml). To-
tal RNA was analyzed for EGR-1
mRNA (20 pg/lane). Lane 1, con-
trol; Lanes 2 and 3, OM treat-
ment for 1 and 3 h; Lanes 4 and
5, TPA treatment for 1 and 3 h;
Lanes 6 and 7, lL-6 treatment for
1 and 3 h; Lane 8, cycloheximide
treatment for 3 h.
Concentration (ng/mI)
naling pathway. TPA behaves similarly to OM in pre-
venting A375 cell proliferation. Unlike OM, however,
TPA treatment causes a robust induction of ECR-l mRNA.
If the binding of OM to its receptor activates PKC in
these cells, then one might expect to see ECR-1 induc-
tion. This did not occur. A similar conclusion concerning
the lack of a PKC response can be drawn from a variant
subclone of A375 cells that is resistant to OM. The
replication of these cells, which possess normal levels of
OM receptor,3 was unaffected by high concentrations of
OM but retained a sensitivity to TPA. The observation
that PKC may not be involved in OM signaling was
unexpected because this pathway is thought to mediate
OM regulation of LDL receptors in HepC2 cells (8). These
differences suggest that OM may utilize different signal-
ing pathways in different cell types.
In conclusion, our data show that the proliferative and
differentiative effects of OM are associated with the
regulation of immediate-early genes ECR-1, c-/un, and c-
myc. The inhibitory response of OM on human mela-
noma cells does not involve these early response genes
or the PKC pathway. This work provides an important
basis for further understanding the sequence of genetic
changes that lead to alterations in cellular phenotype
induced by oncostatin M.
Materials and Methods
Cell Lines. Murine myeloid leukemic Ml cells were ob-
tamed from the American Tissue Culture Collection
(Rockville, MD) and cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine
serum, streptomycin (100 ￿zg/mI), and penicillin (100
units/mi). Normal human fibroblast cells, human A375
melanoma cells, and the variant subclone 4-1.10” (from
Bristol-Myers Squibb) were cultured in Dulbecco’s mod-
ified Eagle’s medium containing 10% heat-inactivated
fetal bovine serum, streptomycin (100 ￿tg/ml), and peni-
cillin (100 units/mI). Cells were incubated at 37#{176}C in 6%
CO2 and were passaged using PBS containing 0.05%
trypsin and 0.02% EDTA.
Cell Proliferation Assays. Cells were incubated over-
night in 96-well tissue culture plates (Costar, Cambridge,
MA) in DMEM (100 j.zl/well) containing 5% serum at a
concentration of 2000-4000 cells/well. Cultures were
refed and incubated with the same culture medium
supplemented with various test factors. Two days later,
cells were incubated in medium containing 5-[125l]iodo-
2’-deoxyuridmne (0.1 ￿Ci/welI) for 6 h, washed with PBS,
fixed in 95% methanol, and air dried. Cell pellets were
solubilized with 200 ￿l of 1 N sodium hydroxide, and the
amount of 1251 incorporated into DNA was measured
using a gamma radiation counter. Ml cells were pulsed
with [3H]thymidmne (0.1 ffCi/mI) for 4 h. The specific
incorporation was determined by harvesting and count-
ing on a LKB 1205 Betaplate counter. The differences in
counts per minute incorporated between experimental
and control cultures were used as the index for growth.
Each data point represents the average from triplicate
cultures. Pure recombinant OM (2) was stored at a con-
centration of 500 ffg/mI in 0.1% trifluoroacetic acid and
40% acetonitrile at 4#{176}C. lL-6 (10 ￿tg/ml in PBS) was
purchased from Amgen Biologicals (Thousand Oaks, CA),
and TPA (5 mg/mI in Me2SO) was from Sigma (St. Louis,
MO).
Preparation of Probes. The 3.1-kb murine Egr-1 cDNA
(kindly provided by Dr. V. P. Sukhatme, University of
Chicago) was purified from plasmid pUC13 after diges-
tion with EcoRI. The human c-jun cDNA (2.6 kb) was
purified from plasmid vector pGEM2 after digestion with
EcoRl. The human c-fos genomic probe (9 kb) was purl-
fled from plasmid vector pBR322 after digestion with
EcoRl. The human y-actin cDNA probe (1.0 kb) and the
human c-myc genomic probe (exon 3, 1.2 kb) were
kindly provided by Dr. Jill Lacy (Yale University). For
mRNA detection, purified inserts were radiolabeled to a
specific activity of 10￿ cpm/￿g using [32P}dCTP (Amer-
sham, Arlington Heights, IL) and purified by G-50 Seph-
adex columns.
RNA isolation and Northern Blot Analysis. Cells were
lysed in guanidmnium isothiocyanate, and total RNA was
isolated by ultracentrifugation through a cesium chloride
cushion (39). Total RNA (10-30 ffg/lane) was separatedA￿#{176} B 120
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Fig. 5. Induction of EGR-1 by TPA in both OM-sensitive and -resistant A375 cell lines. In a growth-inhibitory assay, A375 cells and a clone of A375 (4-
1.10) were incubated with OM (A) or TPA (B) for 3 days. In a parallel experiment (C), both cell lines were treated with TPA (100 ng/mI) in the presence
or absence of OM at the indicated doses for 1 h. Total RNA (20 pg/lane) was analyzed for EGR-1 mRNA. Lane C, control.
by electrophoresis in 1.2% agarose gels containing 6%
formaldehyde and transferred onto nitrocellulose mem-
branes. Cels were routinely stained with ethidium bro-
mide prior to blotting to confirm that equivalent amounts
of RNA were assayed. The prehybridization, hybridiza-
tion, and washing conditions were conducted as previ-
ously described (33). The filters were exposed to Kodak
XAR film with an intensifying screen at -70#{176}Cfor 1-3
days. Differences in hybridization signal were quantitated
using a LKB Ultrascan XL densitometer. Where indicated,
the blots were stripped and reprobed with ‘y-actin to
verify that equivalent amounts of RNA were being
assayed.
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